![]() Christopher Ianelli, M.D., Ph.D., iSpecimen Founder and CEO. “Adding Acutis to the iSpecimen Marketplace ecosystem enables the platform to become even more of a full-service, one-stop-shop for researchers looking to find highly sought-after samples and genetic information for their medical research,” added Dr. “Furthermore, our investment in personnel, technology and other essential resources allows us to provide high-quality, whole genome sequencing to iSpecimen for COVID-19 remnants, tumor samples, and other biospecimens of interest.” “This important initiative between Acutis and iSpecimen highlights our ongoing efforts to advance research in the areas of oncology and COVID-19 today,” said Jibreel Sarij, Acutis CEO. By offering sequencing services for specimens procured on iSpecimen’s platform, researchers can now identify desired samples and receive corresponding sequencing data from a single source instead of vetting and contracting with external sequencing service provider partners. Through the Acutis relationship, iSpecimen will now offer sequencing services to its research community that can help researchers better understand genetic mutations and their impact on diseases such as COVID-19 and cancer.Ĭancer and COVID-19 are currently the second and third leading causes of death in the U.S., respectively. As such, biospecimen samples for these diseases, along with corresponding sequencing data, remain in high demand among researchers who are working on the development of novel diagnostics and therapeutics that could lead to lifesaving medical interventions. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global online biospecimen marketplace that enables life scientists to search across a federated network of healthcare providers for biospecimens needed for medical research, today announced that it added Acutis Diagnostics (“Acutis”), a clinical diagnostics laboratory, to its platform as a laboratory services provider. Sophia has formed a series of partnerships to embed DDM into molecular tests, including recent ones with Agilent Technologies and with the Synergy Oncology division of Synergy Laboratories for a new tumor profiling assay.LEXINGTON, Mass., Ap(GLOBE NEWSWIRE) - iSpecimen Inc. "Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research." ![]() "The use of Sophia DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled," Acutis CSO and Executive VP Abdel Halim said in a statement. The new product will also support retrospective analysis to explain clinical outcomes and assist in target discovery. Under the new collaboration, Hicksville, New York-based Acutis will combine Sophia's DDM for Hereditary Cancers module with its own laboratory analysis technologies to create a next-generation sequencing test to screen patients for eligibility in clinical trials. NEW YORK – Sophia Genetics said Tuesday that Acutis Diagnostics will incorporate the Sophia DDM analytics platform into a new genomic assay to support clinical research and therapeutic development for hereditary cancers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |